

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorials**

**991** Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs  
*J D Isaacs, G R Burmester*

**993** Kawasaki disease or Kawasaki syndrome?  
*A Ravelli, A Martini*

**Heroes and pillars of rheumatology**

**996** Eric Bywaters a life story: 1 June 1910 to 2 April 2003  
*D Isenberg*

**Epidemiology**

**999** Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort  
*M Pouletty, C Borocco, N Ouldali, M Caseris, R Basmaci, N Lachaume, P Bensaid, S Pichard, H Kouider, G Morelle, I Craiu, C Pondarre, A Deho, A Maroni, M Oualha, Z Amoura, J Haroche, J Chommeloux, F Bajolle, C Beyler, S Bonacorsi, G Carcelain, I Koné-Paut, B Bader-Meunier, A Faye, U Meinzer, C Galeotti, I Melki*

**1007** Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China  
*C Ye, S Cai, G Shen, H Guan, L Zhou, Y Hu, W Tu, Y Chen, Y Yu, X Wu, Y Chen, J Zhong, L Dong*

**1014** Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017  
*Z Jin, D Wang, H Zhang, J Liang, X Feng, J Zhao, L Sun*

**Rheumatoid arthritis**

**1023** Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study  
*P Emery, G R Burmester, E Naredo, L Sinigaglia, I Lagunes, F Koenigsbauer, P G Conaghan*

**Psoriatic arthritis**

**1031** Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis  
*E Dures, J Taylor, S Shepperd, S Mukherjee, J Robson, I Vlaev, N Walsh, L C Coates*

**1037** Novel and reliable DACTylitis gIObal Sonographic (DACTOS) score in psoriatic arthritis  
*A Zabotti, G Sakellariou, I Tinazzi, L Idolazzi, A Batticciotto, M Canzoni, G Carrara, O De Lucia, F Figus, N Girolimetto, P Macchioni, R McConnell, N Possemato, A Iagnocco*

**1044** Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression  
*A Watad, H Rowe, T Russell, Q Zhou, L K Anderson, A Khan, R Dunsmuir, P Loughenbury, V Borse, A Rao, P A Millner, N L Bragazzi, H Amital, R Cuhbert, M Wittmann, K Sharif, T Kenna, M A Brown, D Newton, C Bridgewood, D G McGonagle*

**Spondyloarthritis**

**1055** Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register  
*R J Hollick, K Stelfox, L E Dean, J Shim, K Walker-Bone, G J Macfarlane*

**1063** MRI of sacroiliac joints for the diagnosis of axial SpA: prevalence of inflammatory and structural lesions in nulliparous, early postpartum and late postpartum women  
*A Hoballah, C Lukas, C Leplat, P Taourel, J-B Pialat, N Sans, S Ramos-Pascual, C Cyteval*

**Systemic lupus erythematosus**

**1070** Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis  
*C C Mok, L Y Ho, S K Y Ying, M C Leung, C H To, W L Ng*

MORE CONTENTS ►



Member since 2008

.JM00004

This journal is a member of and subscribes to the principles of the

Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

- 1077** Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis  
*G Moroni, M Gatto, F Tamborini, S Quaglini, F Radice, F Saccon, G Frontini, F Alberici, L Sacchi, V Binda, B Trezzi, A Vaglio, P Messa, R A Sinico, A Doria*

## Systemic sclerosis

- 1084** Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study  
*S van Bijnen, J de Vries-Bouwstra, C H van den Ende, M Boonstra, L Kroft, B Geurts, M Snoeren, A Schouffoer, J Spierings, J M van Laar, T WJ Huizinga, A Voskuyl, E Marijt, W van der Velden, F HJ van den Hoogen, M C Vonk*

## Adult Still's disease

- 1090** Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial  
*C Kedor, J Listing, J Zernicke, A Weiß, F Behrens, N Blank, J C Henes, J Kekow, A Rubbert-Roth, H Schulze-Koops, E Seipelt, C Specker, E Feist*

## Behçet's disease

- 1098** Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study  
*F Fagni, A Bettioli, R Talarico, G Lopalco, E Silvestri, M L Urban, P A J Russo, G Di Scala, G Emmi, D Prisco*

## Osteoarthritis

- 1105** Does cartilage loss cause pain in osteoarthritis and if so, how much?  
*K Bacon, M P LaValley, S R Jafarzadeh, D Felson*
- 1111** TGF $\beta$  attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination  
*G Wang, S Chen, Z Xie, S Shen, W Xu, W Chen, X Li, Y Wu, L Li, B Liu, X Ding, A Qin, S Fan*

## Letters

- 1121** Patient discussions of glucocorticoid-related side effects within an online health community forum  
*A Vivekanantham, M Belousov, L Hassan, G Nenadic, W G Dixon*
- 1122** Gender disparity in authorship of guidelines and recommendations in rheumatology  
*G Adami, C Benini, E Vantaggiato, D Rotta, O Viapiana, D Gatti, M Rossini, A Iagnocco*
- 1123** Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database  
*M Hughes, C Heal, E Siegert, E Hachulla, P Airó, A Riccardi, O Distler, M Matucci-Cerinic, On behalf of the EUSTAR Collaborators*
- 1125** Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis  
*S Kuwabara, S Tanimura, S Matsumoto, H Nakamura, T Horita*
- 1126** Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study  
*A Latourte, H-K Ea, A Frazier, A Blanchard, F Lioté, H Marotte, T Bardin, P Richette*

## Electronic pages

- e90** Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis *et al*  
*N Costedoat-Chalumeau, D Isenberg, M Petri*
- e91** Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis *et al*' by Costedoat-Chalumeau *et al*  
*A Fanouriakis, G Bertsias, D T Boumpas*
- e92** Decision-making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat?  
*C Deng, X Qu, S Cheng, X Zeng, Y Li, Y Fei*
- e93** Response to 'Decision making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat?' by Deng *et al*  
*L E C Andrade, J Damoiseaux, E K Chan*

- e94** Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero  
*H Satis, R Bilici Salman, A Avanoğlu Güler, H Karadeniz, Ş Yıldız, N Kayahan*
- e95** Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: 'Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero' by Satis *et al*  
*J Mofors, S-E Sonesson, M Wahren-Herlenius*
- e96** Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh *et al*  
*Z Yang, Y Liang*
- e97** Response to: 'Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S *et al*' by Yang *et al*  
*S Sabbagh, I Pinal Fernandez, F W Miller, L G Rider, A L Mammen*
- e98** Differentiating disease activity from damage in systemic sclerosis: it's still early days!  
*S Jain, S K Sharma*
- e99** Response to: 'Differentiating disease activity from damage in systemic sclerosis: it's still early days!' by Jain and Sharma  
*M Nikpour, On behalf of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) Working Group*
- e100** Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones *et al*  
*F A Vandergheynst, C Lelubre*
- e101** Response to: 'Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones *et al*' by Vandergheynst *et al*  
*R B Jones, T F Hiemstra, M Walsh, D Jayne, L Harper*
- e102** Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone  
*M Samson, B Bonnotte*
- e103** Longitudinal versus cross-sectional IL-6 measurements in tocilizumab-treated GCA. Response to: 'Analysis of IL-6 measurement in GCA patients treated with tocilizumab should consider concomitant treatment with prednisone' by Samson and Bonnotte  
*C T Berger, T Daikeler*